Skip to content
value.today

Decoy Therapeutics Inc.

DCOY
$2 Mmarket cap on Oct 23, 2026
Compare
World rank
#27,622
Revenue
—
For year ending December-2025
Net income
$-13 M
SEC filing
Employees
—

Decoy Therapeutics Inc. in brief

Decoy Therapeutics Inc. is a listed company in the Biotechnology industry, based in Houston, Texas, USA. Its market value was $2 M on 23 October 2026, which makes it the 27,622nd largest listed company in the world and the 4,483rd largest in the USA on this site. Its shares trade under the symbol DCOY (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Decoy Therapeutics Inc.

We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP3ACT™ platform. Our IMP3ACT™ platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. Peptide conjugates are emerging as a major therapeutic drug modality, with the potential to transform multiple therapeutic areas. Utilizing our novel IMP3ACT platform that increases the drug development speed and reduce the complexity of variant synthesis, we aim to build a robust portfolio of novel peptide conjugate therapeutics, initially focusing on infectious diseases and oncology, with the goal of becoming a fully integrated biopharmaceutical company at the forefront of this field. Through this approach, we intend to revolutionize the design, development, and commercialization of peptide conjugate therapeutics. We have no products approved for commercial sales and have not generated any revenue from product sales.

From the company's annual report filed with the US SEC: read the report

Decoy Therapeutics Inc. timeline

5 events, 2014–2026
  1. 2014
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2015
  4. 🔔
    Initial public offering as Flex Pharma, Inc.
    Final prospectus filed with the SEC on 29 January 2015; shares registered for exchange trading on 23 January 2015.
  5. 2019
  6. ✎
    Renamed Salarius Pharmaceuticals, Inc.
    Formerly Flex Pharma, Inc..
  7. 2020
  8. 💰
    Record revenue of $5 million
    FY2020, the highest of the 4 years on record.
  9. 2026
  10. ✎
    Renamed Decoy Therapeutics Inc.
    Formerly Salarius Pharmaceuticals, Inc..

Events of Decoy Therapeutics Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1 M$2 M$3 M$4 M

World rank over time

▼ down 368 places since 2026
2026-10-09: #27259#27,25920262026-10-23: #27627#27,6272026

Rank in USA: #4,389 (Oct 2026) · #4,485 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.4×
Free cash flow yield
-219.9%
Net margin
—
Operating margin
—
Return on equity
-212.6%
Liabilities / assets
46.7%
Revenue growth
-64.8%
R&D / revenue
464.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $2M, net income $-2M$2MFY18Fiscal year ending Dec 2019: revenue $3M, net income $-7M$3MFY19Fiscal year ending Dec 2020: revenue $5M, net income $-7M$5MFY20Fiscal year ending Dec 2021: revenue $2M, net income $-13M$2MFY21Fiscal year ending Dec 2022: revenue —, net income $-32M—FY22Fiscal year ending Dec 2023: revenue —, net income $-13M—FY23Fiscal year ending Dec 2024: revenue —, net income $-6M—FY24Fiscal year ending Dec 2025: revenue —, net income $-13M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-13M$-13M—
Dec 2024——$-6M$-6M—
Dec 2023——$-13M$-13M—
Dec 2022——$-32M$-32M—
Dec 2021$2M-64.8%$-13M$-13M-694.0%
Dec 2020$5M+50.7%$-8M$-7M-140.5%
Dec 2019$3M+77.9%$-8M$-7M-200.0%
Dec 2018$2M—$-2M$-2M-85.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M$1M$-5M$-129.10—
Dec 2024$-5M$0M$-5M$-69.54—
Dec 2023$-13M——$-30.74—
Dec 2022$-18M——$-14.88—
Dec 2021$-10M$0M$-10M$-7.72—
Dec 2020$-10M$0M$-10M$-0.50—
Dec 2019$-12M$0M$-12M$-2.12—
Dec 2018$4M$0M$4M$-1.16—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-1M—Dec ’24Three months to Mar 2025: revenue —, net income $-2M—Mar ’25Three months to Jun 2025: revenue —, net income $-1M—Jun ’25Three months to Sep 2025: revenue —, net income $-1M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-9M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue $0M, net income $-2M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-3M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Decoy Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-13 M
Net income
$-13 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$11 M
Total liabilities
$5 M
Total equity
$6 M

As of December-2025

Top 6 institutional investors in Decoy Therapeutics Inc.#

As of Sep 30, 2026
6 institutions held 44,485 shares (about 1.9% of the shares outstanding) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 6 largest institutional investors in Decoy Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Commonwealth Equity Services, LLC32,000New1.34%$0 MNov 2, 2026
2UBS Group AG4,525+4,500 (+18000.00%)0.19%$0 MNov 10, 2026
3Vanguard Capital Management LLC4,0340 (0.00%)0.17%$0 MNov 13, 2026
4Tower Research Capital LLC (TRC)3,735+3,479 (+1358.98%)0.16%$0 MNov 16, 2026
5SBI Securities Co., Ltd.111New0.00%$0 MOct 22, 2026
6Jpmorgan Chase & Co80New0.00%$0 MNov 12, 2026

Mutual funds holding Decoy Therapeutics Inc.#

3 funds hold shares worth $0 M (about 0.4% of the company). Since their previous reports 1 added shares and 2 sold, selling $0 M net.
Mutual funds holding Decoy Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC5,156$0 M0.22%<0.01%−83%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.4,034$0 M0.17%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC477$0 M0.02%<0.01%−85%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Decoy Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$20 K
2 purchases, 2 insiders
Sold, 12 months
$17
2 sales, 1 insider
Net, 12 months
$20 K
open market only
Insiders on file
24
since
$20 K-$17$0Nov 2025: bought $20 K (2 trades), sold $0 (0 trades)Nov 25Dec 2025: bought $0 (0 trades), sold $17 (2 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
Decoy Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Mark J. RosenblumChief Financial OfficerGrant or award+9,682——11,363Form 4
filed Tess BurlesonDirectorGrant or award+2,000——2,002Form 4
filed Peter Klaus MarschelChief Business OfficerGrant or award+3,900——3,900Form 4
filed Barbara Louise HibnerChief Scientific OfficerGrant or award+4,216——4,216Form 4
filed Patricia G. GauthierDirectorGrant or award+2,000——2,000Form 4
filed Frederick Pierce IIChief Executive OfficerGrant or award+33,455——34,844Form 4
filed Paul LammersDirectorGrant or award+2,000——2,001Form 4
filed Arnold C. HanishDirectorGrant or award+3,000——3,418Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Decoy Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
99,728
18.7% of shares · 1.82 days to cover
Shares sold short, last 20 reportsAll stocks →

Stock splits: 1-for-14.99 reverse split ; 1-for-8 reverse split ; 1-for-25 reverse split ; 1-for-4.28 reverse split

Trading halts

  • 2026-09-22 16:51 UTC, code LUDP, resumed 16:56 UTC
  • 2026-06-29 13:37 UTC, code LUDP, resumed 13:42 UTC
  • 2026-06-29 13:31 UTC, code LUDP, resumed 13:36 UTC
  • 2026-06-09 16:01 UTC, code LUDP, resumed 16:06 UTC
  • 2026-06-09 15:53 UTC, code LUDP, resumed 15:58 UTC

Fails to deliver

  • : 729 shares at $1.03
  • : 5,103 shares at $1.07
  • : 91 shares at $1.17
  • : 343 shares at $1.17
  • : 1,947 shares at $1.52

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Decoy Therapeutics Inc. scorecard#

Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 23, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.4×Price to book 0.4× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-129.10 vs -69.54Diluted EPS -129.10 in fiscal 2025 against -69.54 the year before (report's currency).
    • ✗Net income higher than five years earlier-$13 M-$13 M in fiscal 2025 against -$7 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-338.4%-338.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.13 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year21.2%Diluted shares up 21.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Decoy Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Decoy Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue———01.85.23.52.0r1.31.0
Cost of revenue———————0.40.50.7
Research and development0.40.87.2168.56.94.01.3r1720
General and administrative3.75.05.77.16.16.17.72.3r1920
Operating expenses135.713321513123.6r3641
Operating income−13−5.7−13−32−13−7.8−8.3−1.7r−35−40
Income tax0—————0———
Income from continuing operations—————−7.4−6.9r−1.7——
Income from discontinued operations——————0.00——
Net income attributable to shareholders−13−5.6−13−32−13−7.4−6.9−1.7r−34−39
Earnings per share, basic-129.10-69.54r-30.74r-14.88-7.72r-0.50-2.12-1.16r-1.99-2.43
Earnings per share, diluted-129.10-69.54r-30.74r-14.88-7.72r-0.50-2.12-1.16r-1.99-2.43
Shares, weighted average (basic)0.10.1r0.4r2.11.7r16————
Shares, weighted average (diluted)0.10.1r0.4r2.11.7r163.31.5r1716
Balance sheet
Cash and cash equivalents112.45.91229113.73.2r1922
Short-term investments———————01439
Receivables————1.63.9r00.00.00.0
Inventory———————0.20.40.5
Other current assets0.30.00.20.20.20.10.10.0r0.80.9
Current assets113.06.51530164.76.4r3562
Property, plant and equipment0.00——0.00.00.00.0r0.30.6
Goodwill———08.98.98.90——
Total assets113.06.6154125146.6r3563
Accounts payable0.90.90.62.91.51.91.80.4r2.01.2
Current liabilities5.21.5—————1.15.83.9
Total liabilities5.21.51.34.32.12.83.37.9r5.93.9
Retained earnings−94−82−76−64−32−19−12−5.1r−111−77
Shareholders' equity5.91.55.310392211−1.3r−2.9r59
Total liabilities and equity113.06.6154125146.6r3563
Shares outstanding0.5r0.1r0.5r2.31.8r244.52.0r1817
Cash-flow statement
Depreciation and amortization0.00.00.00.00.00.00.10.0——
Share-based compensation0.20.30.50.80.60.30.80.0r4.26.6
Cash from operating activities−4.8−4.5−13−18−10−10−124.2r−28−32r
Capital expenditure−0.60——0−0.000−0.1−0.6
Cash from investing activities0.800−1.50−0.05.60r24−12
Shares issued———————2.9——
Dividends paid—————0−0.10——
Cash from financing activities121.16.62.028183.61.4r0.00.0
Change in cash8.3−3.5−6.2−17187.4−2.45.6r−3.2−44
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Decoy Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 4 · Unregistered share sale 3 · Shareholder rights changed 3 · Bylaws or fiscal year changed 3 · Shareholder vote 5

Decoy Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Delisting notice8-K
Shareholder vote8-K
Directors and officers8-K
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Material agreementShareholder rights changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 23, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Decoy Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$6 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Apr 2022$2 MPrivate placement after listing$2 to $10 million4optionsSEC
Jul 2014$16 MNo. 1$10 to $50 million20equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Decoy Therapeutics Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2018–2018
Latest
—
2018-06-08
Decoy Therapeutics Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2018············—
Decoy Therapeutics Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
60% of workforceRestructuring planSEC 8-K“In connection with the restructuring plan, the Company plans to reduce its workforce by approximately 60%, with the majority of the reduction in personnel expected to be completed …”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Decoy Therapeutics Inc. compares in Biotechnology

  • Market cap$2 M · higher than 2% of 726
  • Revenue growth-64.8% · higher than 14% of 438
  • Price / book0.4× · lower than 94% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Decoy Therapeutics Inc.🇺🇸$2 M——-64.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 23, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Decoy Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Decoy Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Decoy Therapeutics Inc.? Suggest a correction